Illumina Inc. Reports Decline in Q3 Profit, Surpassing Expectations
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Oct 30 2025
0mins
Should l Buy ILMN?
Source: NASDAQ.COM
Third Quarter Earnings: Illumina Inc. reported a profit of $150 million, or $0.98 per share, for the third quarter, a decrease from $705 million, or $4.42 per share, in the same period last year, but still beating analyst expectations.
Adjusted Earnings: Excluding special items, the company reported adjusted earnings of $206 million, or $1.34 per share, surpassing the average analyst estimate of $1.17 per share.
Revenue Growth: The company's revenue increased by 0.4% to $1.084 billion compared to $1.080 billion in the previous year.
Future Guidance: Illumina provided full-year EPS guidance in the range of $4.65 to $4.75.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ILMN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ILMN
Wall Street analysts forecast ILMN stock price to rise
13 Analyst Rating
4 Buy
6 Hold
3 Sell
Hold
Current: 120.810
Low
40.50
Averages
133.54
High
170.00
Current: 120.810
Low
40.50
Averages
133.54
High
170.00
About ILMN
Illumina, Inc. specializes in DNA sequencing and array-based technologies, serving customers in research, clinical and applied markets. The Company's products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. Its comprehensive line of products addresses the scale of experimentation and breadth of functional analysis to advance disease research, drug development, and the development of molecular tests. It also specializes in data-driven proteomics technology. Its products include instruments, kits and reagents, selection tools, and software and analysis. Its services include sequencing services, microarray services, proactive instrument monitoring, and instrument services and training.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
CNBC Launches Advocacy Platform for Rare Diseases
- Platform Launch: CNBC launched the CNBC Cures platform on January 8, aimed at giving a voice to the 30 million Americans living with rare diseases, connecting them with existing advocacy groups to drive attention and support from the medical community.
- Audience Engagement: The CNBC Cures newsletter has surpassed 20,000 subscribers, making it one of the fastest-growing newsletters on the network, indicating strong viewer interest and support for rare disease topics.
- Social Media Impact: Cures-related videos have garnered 1 million views across Facebook, TikTok, Instagram, and LinkedIn, demonstrating significant outreach and enhancing public awareness of rare diseases.
- Successful Summit: The inaugural CNBC Cures Summit attracted notable figures like Warren Buffett and sold out shortly after registration opened, with over 8,000 views for the livestream, reflecting heightened societal attention and support for rare disease issues.
See More
Illumina and Labcorp Expand Precision Oncology Collaboration
- Collaboration Deepening: Illumina and Labcorp announced an expanded collaboration aimed at enhancing precision oncology through next-generation sequencing solutions, with expectations to promote equitable access to cancer biomarker testing, thereby improving patient testing convenience.
- New Test Development: The companies will jointly develop tests addressing unmet needs, covering advanced oncology research and in vitro diagnostic tests, aiming to bridge existing gaps in precision oncology and improve patient treatment outcomes.
- Co-Commercialization: Plans include co-commercializing Labcorp's FDA-authorized liquid biopsy assay PGDx elio® plasma focus™ Dx alongside Illumina's FDA-approved TruSight™ Oncology Comprehensive, intended to provide broader access to both tissue and liquid biopsy testing for hospitals and community health systems.
- Clinical Utility Research: The companies will continue joint efforts to demonstrate the clinical utility of CGP, with studies showing that CGP detected variants in over 72% of non-small cell lung cancer patient tumors that are relevant to current targeted therapies or clinical trials, further advancing the application of precision medicine.
See More
Illumina and Veritas Collaborate to Advance Genomics in Healthcare
- Strategic Collaboration Launched: Illumina and Veritas Genetics have formed a consortium aimed at integrating whole-genome sequencing into everyday healthcare through health insurance plans in the U.S. and global markets, setting a new standard for proactive health management.
- Data-Driven Precision Medicine: The collaboration combines clinical-grade sequencing, advanced informatics, and member-ready reporting to support an integrated data ecosystem that enhances research, drug discovery, and clinical trial optimization, thereby improving overall healthcare efficiency.
- Personalized Health Services: Veritas' myGenome whole-genome sequencing service is designed to integrate into health insurer environments, enabling members to benefit from preventive genomics at a personalized level, facilitating earlier disease risk identification and tailored prevention strategies.
- Transforming Healthcare Models: The consortium aims to shift care from reactive treatment to proactive prevention by identifying risks in hereditary cancer, cardiometabolic diseases, and medication responses, further expanding the clinical utility of genomics and supporting scalable, evidence-based adoption across the healthcare ecosystem.
See More
Illumina and Veritas Collaborate to Advance Genomics in Healthcare
- Strategic Collaboration Launched: Illumina and Veritas Genetics have formed a consortium aimed at integrating whole-genome sequencing into everyday healthcare through health insurance plans in the U.S. and global markets, setting a new standard for proactive health management.
- Data-Driven Health Management: This collaboration combines clinical-grade sequencing, advanced informatics, and member-ready reporting to support an integrated data ecosystem that enhances research, drug discovery, and clinical trial optimization, thereby improving overall healthcare quality.
- Personalized Prevention Strategies: Through the myGenome whole-genome sequencing service, members can benefit from preventive genomics at a personalized level, enabling earlier disease risk identification and improving long-term health outcomes, thus shifting care from reactive treatment to proactive prevention.
- Industry Collaboration Opportunities: The consortium aims to create an integrated clinical-genomics dataset to facilitate industry partnerships in precision medicine, helping identify elevated risks in hereditary cancer, cardiometabolic diseases, and medication responses, further advancing the clinical utility of genomics.
See More
Genomic Alliance Dataset Expands to 312,000 Whole Genomes
- Dataset Expansion: The Alliance for Genomic Discovery (AGD) expands its core dataset to 312,000 whole genomes by adding 50,000 additional whole genomes paired with proteomic data, significantly enhancing the depth and breadth of clinical data to support drug discovery.
- Multiomic Integration: GSK, as one of the first participants, drives the multiomic expansion of AGD by utilizing Illumina's Protein Prep technology, which adds molecular depth to the dataset aimed at accelerating target discovery and therapy development, thereby improving drug development efficiency.
- Clinical Data Advantage: The AGD dataset combines deep clinical data from a leading academic medical center, enabling more precise definitions of disease cohorts and facilitating impactful research in areas such as autoimmune diseases and obesity, showcasing its significant clinical application value.
- Strengthened Partnerships: The addition of RGC not only expands the AGD database scale but also enhances collaboration with Illumina and the biopharma community, promoting the construction of large-scale population genomics and driving innovation and efficiency in new drug development.
See More
Genomic Alliance Dataset Expands to 312,000 Whole Genomes
- Dataset Expansion: The Alliance for Genomic Discovery (AGD) expands its core dataset to 312,000 whole genomes with the addition of Regeneron Genetics Center as the tenth member, significantly enhancing the depth and breadth of clinical data, thereby providing a stronger foundation for drug discovery.
- Multiomic Data Integration: GSK, as one of the first participants, drives the pairing of 50,000 whole genomes with proteomic data, aimed at accelerating target discovery and therapy development, thus improving the efficiency and precision of drug research.
- Clinical Data Advantage: The AGD dataset combines deep clinical data from a leading academic medical center, enabling more precise definitions of disease cohorts and facilitating research advancements in areas such as autoimmune diseases and obesity, thereby fostering innovation in drug development.
- Strengthened Partnerships: Through collaboration with Illumina and Regeneron, AGD plans to continue expanding its database, leveraging large-scale human genomic data to drive the discovery of new drug targets and enhance the efficiency and effectiveness of clinical R&D.
See More
CNBC Launches Advocacy Platform for Rare Diseases
- Platform Launch: CNBC launched the CNBC Cures platform on January 8, aimed at giving a voice to the 30 million Americans living with rare diseases, connecting them with existing advocacy groups to drive attention and support from the medical community.
- Audience Engagement: The CNBC Cures newsletter has surpassed 20,000 subscribers, making it one of the fastest-growing newsletters on the network, indicating strong viewer interest and support for rare disease topics.
- Social Media Impact: Cures-related videos have garnered 1 million views across Facebook, TikTok, Instagram, and LinkedIn, demonstrating significant outreach and enhancing public awareness of rare diseases.
- Successful Summit: The inaugural CNBC Cures Summit attracted notable figures like Warren Buffett and sold out shortly after registration opened, with over 8,000 views for the livestream, reflecting heightened societal attention and support for rare disease issues.
See More
Illumina and Labcorp Expand Precision Oncology Collaboration
- Collaboration Deepening: Illumina and Labcorp announced an expanded collaboration aimed at enhancing precision oncology through next-generation sequencing solutions, with expectations to promote equitable access to cancer biomarker testing, thereby improving patient testing convenience.
- New Test Development: The companies will jointly develop tests addressing unmet needs, covering advanced oncology research and in vitro diagnostic tests, aiming to bridge existing gaps in precision oncology and improve patient treatment outcomes.
- Co-Commercialization: Plans include co-commercializing Labcorp's FDA-authorized liquid biopsy assay PGDx elio® plasma focus™ Dx alongside Illumina's FDA-approved TruSight™ Oncology Comprehensive, intended to provide broader access to both tissue and liquid biopsy testing for hospitals and community health systems.
- Clinical Utility Research: The companies will continue joint efforts to demonstrate the clinical utility of CGP, with studies showing that CGP detected variants in over 72% of non-small cell lung cancer patient tumors that are relevant to current targeted therapies or clinical trials, further advancing the application of precision medicine.
See More
Illumina and Veritas Collaborate to Advance Genomics in Healthcare
- Strategic Collaboration Launched: Illumina and Veritas Genetics have formed a consortium aimed at integrating whole-genome sequencing into everyday healthcare through health insurance plans in the U.S. and global markets, setting a new standard for proactive health management.
- Data-Driven Precision Medicine: The collaboration combines clinical-grade sequencing, advanced informatics, and member-ready reporting to support an integrated data ecosystem that enhances research, drug discovery, and clinical trial optimization, thereby improving overall healthcare efficiency.
- Personalized Health Services: Veritas' myGenome whole-genome sequencing service is designed to integrate into health insurer environments, enabling members to benefit from preventive genomics at a personalized level, facilitating earlier disease risk identification and tailored prevention strategies.
- Transforming Healthcare Models: The consortium aims to shift care from reactive treatment to proactive prevention by identifying risks in hereditary cancer, cardiometabolic diseases, and medication responses, further expanding the clinical utility of genomics and supporting scalable, evidence-based adoption across the healthcare ecosystem.
See More
Illumina and Veritas Collaborate to Advance Genomics in Healthcare
- Strategic Collaboration Launched: Illumina and Veritas Genetics have formed a consortium aimed at integrating whole-genome sequencing into everyday healthcare through health insurance plans in the U.S. and global markets, setting a new standard for proactive health management.
- Data-Driven Health Management: This collaboration combines clinical-grade sequencing, advanced informatics, and member-ready reporting to support an integrated data ecosystem that enhances research, drug discovery, and clinical trial optimization, thereby improving overall healthcare quality.
- Personalized Prevention Strategies: Through the myGenome whole-genome sequencing service, members can benefit from preventive genomics at a personalized level, enabling earlier disease risk identification and improving long-term health outcomes, thus shifting care from reactive treatment to proactive prevention.
- Industry Collaboration Opportunities: The consortium aims to create an integrated clinical-genomics dataset to facilitate industry partnerships in precision medicine, helping identify elevated risks in hereditary cancer, cardiometabolic diseases, and medication responses, further advancing the clinical utility of genomics.
See More
Genomic Alliance Dataset Expands to 312,000 Whole Genomes
- Dataset Expansion: The Alliance for Genomic Discovery (AGD) expands its core dataset to 312,000 whole genomes by adding 50,000 additional whole genomes paired with proteomic data, significantly enhancing the depth and breadth of clinical data to support drug discovery.
- Multiomic Integration: GSK, as one of the first participants, drives the multiomic expansion of AGD by utilizing Illumina's Protein Prep technology, which adds molecular depth to the dataset aimed at accelerating target discovery and therapy development, thereby improving drug development efficiency.
- Clinical Data Advantage: The AGD dataset combines deep clinical data from a leading academic medical center, enabling more precise definitions of disease cohorts and facilitating impactful research in areas such as autoimmune diseases and obesity, showcasing its significant clinical application value.
- Strengthened Partnerships: The addition of RGC not only expands the AGD database scale but also enhances collaboration with Illumina and the biopharma community, promoting the construction of large-scale population genomics and driving innovation and efficiency in new drug development.
See More
Genomic Alliance Dataset Expands to 312,000 Whole Genomes
- Dataset Expansion: The Alliance for Genomic Discovery (AGD) expands its core dataset to 312,000 whole genomes with the addition of Regeneron Genetics Center as the tenth member, significantly enhancing the depth and breadth of clinical data, thereby providing a stronger foundation for drug discovery.
- Multiomic Data Integration: GSK, as one of the first participants, drives the pairing of 50,000 whole genomes with proteomic data, aimed at accelerating target discovery and therapy development, thus improving the efficiency and precision of drug research.
- Clinical Data Advantage: The AGD dataset combines deep clinical data from a leading academic medical center, enabling more precise definitions of disease cohorts and facilitating research advancements in areas such as autoimmune diseases and obesity, thereby fostering innovation in drug development.
- Strengthened Partnerships: Through collaboration with Illumina and Regeneron, AGD plans to continue expanding its database, leveraging large-scale human genomic data to drive the discovery of new drug targets and enhance the efficiency and effectiveness of clinical R&D.
See More
